Novel Alzheimer's disease Therapy to Slow Cognitive Decline?

At AAN 2017, Larry Altstiel, MD, PhD, EVP, Chief Medical Officer, vTv Therapeutics, spoke with MD Magazine about his team’s two phase 3 studies in Alzheimer’s disease that studied a “well-established” target called the receptor for advanced glycation endproducts (RAGE).